News Release ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer November 17, 2022 - Houston, Texas ImmunoMet Therapeutics, Inc., a clinical stage…
News Release ImmunoMet Therapeutics Announces Closing of Series C Financing October 19, 2022 - Houston, TexasImmunoMet Therapeutics, a clinical stage biotechnology company targeting cellular metabolism to develop novel anti-tumor and…
News Release Immunomet Therapeutic’s compound featured in the pre-publication from experts at Cambridge University entitled “Structural Basis of Mammalian Respiratory Complex I Inhibition by Medicinal Biguanides” Dr. Judy Hirst and…
News Release Immunomet Therapeutics Inc. announces publication of “First-in-human study of IM156, a novel biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors”. July 14, 2022 - Houston,…
News Release ImmunoMet Therapeutics Closes $10M Series B-1 and Announces Plans to Conduct a Food Effect Study December 31, 2021 - Houston, TexasImmunoMet Therapeutics, Inc., a clinical stage biotechnology company…
News Release ImmunoMet Therapeutics Completes Phase 1 Study in Healthy Volunteers and Establishes Target Engagement for IM156 November 3, 2021 - Houston, TexasImmunoMet Therapeutics, Inc., a clinical stage biotechnology company…
News Release ImmunoMet Therapeutics Granted Fast Track Designation by U.S. FDA for IM156 in Idiopathic Pulmonary Fibrosis HOUSTON, TEXAS May 3, 2021 ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company…
News Release ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Idiopathic Pulmonary Fibrosis and Completes Financing - Phase 1 clinical study recruitment in…
News Release ImmunoMet Therapeutics Announces Acceptance of Abstract for 2020 ASCO Virtual Scientific Program May 20, 2020 - Houston, TexasImmunoMet Therapeutics, a clinical stage biotechnology company targeting cellular metabolism to…
News Release ImmunoMet Therapeutics Announces Closing of Series B Expansion Financing February 5, 2020 - Houston, TexasImmunoMet Therapeutics, a clinical stage biotechnology company targeting cellular metabolism to develop novel anti-tumor…